Oncopeptides AB Market Cap ($69.81 Million)
Market Cap & Net Worth: Oncopeptides AB (ONCO)
Oncopeptides AB market cap. Oncopeptides AB (ST:ONCO) has a market capitalization of $69.81 Million (Skr648.71 Million) as of November 5, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #20402 globally and #362 in its home market, demonstrating a 1.92% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Oncopeptides AB's stock price Skr1.70 by its total outstanding shares 381148118 (381.15 Million). Also see how efficiently does Oncopeptides AB generate cash for how efficiently the company converts equity into cash flow.
Oncopeptides AB Market Cap History (2017–2026)
Oncopeptides AB market cap history from 2017 to 2026. Data shows change from $3.28 Billion to $69.81 Million (-28.31% CAGR). Check Oncopeptides AB stock price for real-time trading data and today's change.
Oncopeptides AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Oncopeptides AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ONCO shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2.77x
Oncopeptides AB's market cap is 2.77 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $6.96 Billion | $19.36 Million | -$1.59 Billion | 359.63x | N/A |
| 2021 | $344.55 Million | $118.30 Million | -$1.43 Billion | 2.91x | N/A |
| 2022 | $498.36 Million | $8.36 Million | -$337.95 Million | 59.65x | N/A |
| 2023 | $314.20 Million | $35.22 Million | -$249.11 Million | 8.92x | N/A |
| 2024 | $63.82 Million | $31.65 Million | -$284.61 Million | 2.02x | N/A |
| 2025 | $197.09 Million | $71.12 Million | -$249.59 Million | 2.77x | N/A |
Competitor Companies of ONCO by Market Capitalization
Companies near Oncopeptides AB in the global market cap rankings as of November 5, 2026. Also see how large is Oncopeptides AB's balance sheet for a full breakdown of the balance sheet.
Key companies related to Oncopeptides AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Oncopeptides AB (2017–2026)
Market capitalization of Oncopeptides AB from 2017 to today. Between 2017 and today, Oncopeptides AB's market cap moved from $3.28 Billion to $ 69.81 Million, with a yearly change of -28.31%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr69.81 Million | -64.58% |
| 2025 | Skr197.09 Million | +208.80% |
| 2024 | Skr63.82 Million | -79.69% |
| 2023 | Skr314.20 Million | -36.95% |
| 2022 | Skr498.36 Million | +44.64% |
| 2021 | Skr344.55 Million | -95.05% |
| 2020 | Skr6.96 Billion | +33.73% |
| 2019 | Skr5.21 Billion | -3.42% |
| 2018 | Skr5.39 Billion | +64.25% |
| 2017 | Skr3.28 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Oncopeptides AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $69.81 Million USD |
| MoneyControl | $69.81 Million USD |
| MarketWatch | $69.81 Million USD |
| marketcap.company | $69.81 Million USD |
| Reuters | $69.81 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Oncopeptides AB
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company's PDC platform desig… Read more